{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:46:35Z","timestamp":1793810795515,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005981","name":"Direktorat Jenderal Pendidikan Tinggi","doi-asserted-by":"publisher","award":["2751\/E4\/KU\/2020"],"award-info":[{"award-number":["2751\/E4\/KU\/2020"]}],"id":[{"id":"10.13039\/501100005981","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00784-021-04331-7","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:03:06Z","timestamp":1641859386000},"page":"2269-2279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-1914","authenticated-orcid":false,"given":"Isti Rahayu","family":"Suryani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraj","family":"Ahmadzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaib","family":"Shujaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhilde","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"4331_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.coms.2015.06.008","volume":"27","author":"SL Ruggiero","year":"2015","unstructured":"Ruggiero SL (2015) Diagnosis and staging of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am 27:479\u2013487. https:\/\/doi.org\/10.1016\/j.coms.2015.06.008","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"4331_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA et al (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 127:117\u2013135. https:\/\/doi.org\/10.1016\/j.oooo.2018.09.008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4331_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler DL et al (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom Off J Int Soc Clin Densitom 20:8\u201324. https:\/\/doi.org\/10.1016\/j.jocd.2016.09.005","journal-title":"J Clin Densitom Off J Int Soc Clin Densitom"},{"key":"4331_CR4","doi-asserted-by":"publisher","unstructured":"Dunphy L, Salzano G, Gerber B, Graystone J (2020) Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. BMJ Case Rep 13: https:\/\/doi.org\/10.1136\/bcr-2018-224455","DOI":"10.1136\/bcr-2018-224455"},{"key":"4331_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg 72:1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031","journal-title":"J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg"},{"key":"4331_CR6","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1177\/0300060518788987","volume":"46","author":"H Holtmann","year":"2018","unstructured":"Holtmann H, Lommen J, K\u00fcbler NR et al (2018) Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials. J Int Med Res 46:4277\u20134296. https:\/\/doi.org\/10.1177\/0300060518788987","journal-title":"J Int Med Res"},{"key":"4331_CR7","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032\u20131045. https:\/\/doi.org\/10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"4331_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S et al (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823\u20131829. https:\/\/doi.org\/10.1097\/JTO.0b013e31826aec2b","journal-title":"J Thorac Oncol"},{"key":"4331_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jcms.2018.05.046","volume":"46","author":"S Aljohani","year":"2018","unstructured":"Aljohani S, Gaudin R, Weiser J et al (2018) Osteonecrosis of the jaw in patients treated with denosumab: a multicenter case series. J cranio-maxillo-facial Surg Off Publ Eur Assoc Cranio-Maxillo-Facial Surg 46:1515\u20131525. https:\/\/doi.org\/10.1016\/j.jcms.2018.05.046","journal-title":"J cranio-maxillo-facial Surg Off Publ Eur Assoc Cranio-Maxillo-Facial Surg"},{"key":"4331_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.23736\/S0026-4970.17.04056-0","volume":"66","author":"G Ghidini","year":"2017","unstructured":"Ghidini G, Manfredi M, Giovannacci I et al (2017) Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs. Minerva Stomatol 66:135\u2013140. https:\/\/doi.org\/10.23736\/S0026-4970.17.04056-0","journal-title":"Minerva Stomatol"},{"key":"4331_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","volume":"13","author":"V Fusco","year":"2015","unstructured":"Fusco V, Porta C, Saia G et al (2015) Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer 13:287\u2013294. https:\/\/doi.org\/10.1016\/j.clgc.2014.12.002","journal-title":"Clin Genitourin Cancer"},{"key":"4331_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"4331_CR13","unstructured":"Wells, G., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M. &, Tugwell P (2007) Newcastle-Ottawa Scale"},{"key":"4331_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72:39. https:\/\/doi.org\/10.1186\/2049-3258-72-39","journal-title":"Arch Public Health"},{"key":"4331_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2020.12.045","author":"Z Feng","year":"2021","unstructured":"Feng Z, An J, Zhang Y (2021) Factors influencing severity of medication-related osteonecrosis of the jaw: a retrospective study. J Oral Maxillofac Surg. https:\/\/doi.org\/10.1016\/j.joms.2020.12.045","journal-title":"J Oral Maxillofac Surg"},{"key":"4331_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/annonc\/mdn630","volume":"20","author":"T Van den Wyngaert","year":"2009","unstructured":"Van den Wyngaert T, Claeys T, Huizing MT et al (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331\u2013336. https:\/\/doi.org\/10.1093\/annonc\/mdn630","journal-title":"Ann Oncol"},{"key":"4331_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000671","volume":"94","author":"KN Pilanci","year":"2015","unstructured":"Pilanci KN, Alco G, Ordu C et al (2015) Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? Med 94:e671. https:\/\/doi.org\/10.1097\/md.0000000000000671","journal-title":"Med"},{"key":"4331_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.oooo.2020.12.018","volume":"131","author":"T Yasui","year":"2021","unstructured":"Yasui T, Kimura M, Nagamine H et al (2021) Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 131:312\u2013318. https:\/\/doi.org\/10.1016\/j.oooo.2020.12.018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4331_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","volume":"30","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa T, Hayashida S, Kondo E et al (2019) Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int 30:231\u2013239. https:\/\/doi.org\/10.1007\/s00198-018-4746-8","journal-title":"Osteoporos Int"},{"key":"4331_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/odi.13046","volume":"25","author":"K McGowan","year":"2019","unstructured":"McGowan K, Acton C, Ivanovski S et al (2019) Systemic comorbidities are associated with medication-related osteonecrosis of the jaws: case-control study. Oral Dis 25:1107\u20131115. https:\/\/doi.org\/10.1111\/odi.13046","journal-title":"Oral Dis"},{"key":"4331_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh IS, Song S et al (2016) Osteonecrosis of the jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS). J Bone Min Res 31:336\u2013340. https:\/\/doi.org\/10.1002\/jbmr.2693","journal-title":"J Bone Min Res"},{"key":"4331_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/cia.S200455","volume":"14","author":"JY Kim","year":"2019","unstructured":"Kim JY, Song HC, Jee HG (2019) Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients. Clin Interv Aging 14:797\u2013804. https:\/\/doi.org\/10.2147\/cia.S200455","journal-title":"Clin Interv Aging"},{"key":"4331_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00520-017-4003-2","volume":"26","author":"M Schiodt","year":"2018","unstructured":"Schiodt M, Vadhan-Raj S, Chambers MS et al (2018) A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26:1905\u20131915. https:\/\/doi.org\/10.1007\/s00520-017-4003-2","journal-title":"Support Care Cancer"},{"key":"4331_CR24","doi-asserted-by":"publisher","unstructured":"Oteri G, Campisi G, Panzarella V, et al (2018) Could the combined administration of bone antiresorptive drug, taxanes, and corticosteroids worsen medication related osteonecrosis of the jaws in cancer patients? Biomed Res Int 2018: https:\/\/doi.org\/10.1155\/2018\/4021952","DOI":"10.1155\/2018\/4021952"},{"key":"4331_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/07357900802208608","volume":"27","author":"JB Aragon-Ching","year":"2009","unstructured":"Aragon-Ching JB, Ning YM, Chen CC et al (2009) Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27:221\u2013226. https:\/\/doi.org\/10.1080\/07357900802208608","journal-title":"Cancer Invest"},{"key":"4331_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","volume":"125","author":"H Abel Mahedi Mohamed","year":"2018","unstructured":"Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M (2018) Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125:157\u2013163. https:\/\/doi.org\/10.1016\/j.oooo.2017.10.010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4331_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347. https:\/\/doi.org\/10.1093\/annonc\/mdr435","journal-title":"Ann Oncol"},{"key":"4331_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","volume":"26","author":"T van Cann","year":"2018","unstructured":"van Cann T, Loyson T, Verbiest A et al (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26:869\u2013878. https:\/\/doi.org\/10.1007\/s00520-017-3903-5","journal-title":"Support Care Cancer"},{"key":"4331_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E et al (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27:383\u2013394. https:\/\/doi.org\/10.1007\/s00520-018-4501-x","journal-title":"Support Care Cancer"},{"key":"4331_CR30","first-page":"87","volume":"14","author":"H Ga\u00eata-araujo","year":"2021","unstructured":"Ga\u00eata-araujo H, Leite AF, Vasconcelos KDF, Coropciuc R (2021) Why do some extraction sites develop medication- related osteonecrosis of the jaw and others do not\u202f? A within-patient study assessing radiographic predictors 14:87\u201398","journal-title":"A within-patient study assessing radiographic predictors"},{"key":"4331_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/odi.12632","volume":"23","author":"P Fung","year":"2017","unstructured":"Fung P, Bedogni G, Bedogni A et al (2017) Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis 23:477\u2013483. https:\/\/doi.org\/10.1111\/odi.12632","journal-title":"Oral Dis"},{"key":"4331_CR32","doi-asserted-by":"publisher","unstructured":"Zhou Y, Yu Y, Shi Y, et al (2020) Combined administration of bisphosphonates, chemotherapeutic agents, and\/or targeted drugs increases the risk for stage 3 medication-related osteonecrosis of the jaw: a 4-year retrospective study. Biomed Res Int https:\/\/doi.org\/10.1155\/2020\/5847429","DOI":"10.1155\/2020\/5847429"},{"key":"4331_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.joms.2015.07.019","volume":"74","author":"CR DeSesa","year":"2016","unstructured":"DeSesa CR, Appugounder S, Haberland C, Johnson MP (2016) Osteonecrosis of the jaw in association with chemotherapy in the setting of cutaneous T-cell lymphoma. J Oral Maxillofac Surg 74:292\u2013301. https:\/\/doi.org\/10.1016\/j.joms.2015.07.019","journal-title":"J Oral Maxillofac Surg"},{"key":"4331_CR34","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","volume":"71","author":"C Tsao","year":"2013","unstructured":"Tsao C, Darby I, Ebeling PR et al (2013) Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg 71:1360\u20131366. https:\/\/doi.org\/10.1016\/j.joms.2013.02.016","journal-title":"J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-021-04331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-021-04331-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-021-04331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T05:27:05Z","timestamp":1646458025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00784-021-04331-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4331"],"URL":"https:\/\/doi.org\/10.1007\/s00784-021-04331-7","relation":{},"ISSN":["1432-6981","1436-3771"],"issn-type":[{"value":"1432-6981","type":"print"},{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animal performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}